Nasdaq: srpt investigation reminder: kessler topaz meltzer & check, llp encourages sarepta therapeutics, inc. (nasdaq: srpt) investors with significant losses to contact the firm

Radnor, pa.--(business wire)-- #classaction--the law firm of kessler topaz meltzer & check, llp (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of sarepta therapeutics, inc. (nasdaq: srpt) (“sarepta”). on march 18, 2025, sarepta issued a press release revealing that a 16-year-old boy had passed away from acute liver failure following treatment with sarepta's gene therapy, elevidys. on this news, sarepta's stock price fell $27.81 per shar.
SRPT Ratings Summary
SRPT Quant Ranking